Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01768338 · ClinicalTrials.gov registry record · Phase 1
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Michael John Robertson.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01768338 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by Michael John Robertson. The registered enrollment target is 9 participants, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01768338, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Michael John Robertson.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG Ofatumumab combined with SB-485232
Study Locations (1)
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-08-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01768338
The ClinicalTrials.gov registry entry for NCT01768338 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (96% lower). The listed sponsor is Michael John Robertson, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Ofatumumab combined with SB-485232 is the first listed.
NCT01768338 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT01768338 about?
NCT01768338 is a clinical study titled "Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma". The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
What is the current status of trial NCT01768338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-02. Estimated completion is 2017-08-03.
What conditions does trial NCT01768338 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01768338?
The interventions under investigation include: Ofatumumab combined with SB-485232 (DRUG).
Who is sponsoring clinical trial NCT01768338?
This trial is sponsored by Michael John Robertson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01768338 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.